OmniAb shares surge 10.50% intraday after unveiling OmniUltra transgenic chickens at antibody conference.

OmniAb surged 10.5% intraday after unveiling its OmniUltra transgenic chickens at the Antibody Engineering & Therapeutics conference. The platform generates ultralong CDRH3 antibodies with broad epitope coverage, offering potential advancements in targeting conserved mammalian proteins. This innovation builds on recent partnerships with ArrowMark and Viking Global for antibody discovery and aligns with the CEO’s emphasis on robust therapeutic platforms highlighted at the Jefferies Conference. The breakthrough positions OmniAb to address persistent challenges in protein-targeting therapies, driving investor optimism about its long-term commercial and scientific potential.